Treatment choice in EGFR-mutant non-small-cell lung cancer

Wolfgang M Brueckl

doi:10.1016/S1470-2045(17)30684-8

Treatment choice in EGFR-mutant non-small-cell lung cancer

Wolfgang M Brueckl^* (First author)

^*Corresponding author for this work

Department of Internal Medicine III, Division of Respiratory Medicine, Allergology and Sleep Medicine

Research output: Contribution to journal › Editorial › peer-review

6 Citations (Web of Science)

Original language	English
Pages (from-to)	1425-1426
Journal	LANCET ONCOL
Volume	18
Issue number	11
DOIs	https://doi.org/10.1016/S1470-2045(17)30684-8
Publication status	Published - 2017

Keywords

SURVIVAL-DATA
AFATINIB
TRIAL
GEFITINIB

Access to Document

10.1016/S1470-2045(17)30684-8

Cite this

@article{816ccee3fea44bd3b7c7d85ae4988b89,

title = "Treatment choice in EGFR-mutant non-small-cell lung cancer",

keywords = "SURVIVAL-DATA, AFATINIB, TRIAL, GEFITINIB",

author = "Brueckl, {Wolfgang M}",

note = "Brueckl: Paracelsus Med Univ, Gen Hosp Nuernberg, Dept Resp Med Allergol Sleep Med, Nurnberg, Germany",

year = "2017",

doi = "10.1016/S1470-2045(17)30684-8",

language = "English",

volume = "18",

pages = "1425--1426",

journal = "LANCET ONCOL",

issn = "1470-2045",

publisher = "Elsevier ",

number = "11",

}

TY - JOUR

T1 - Treatment choice in EGFR-mutant non-small-cell lung cancer

AU - Brueckl, Wolfgang M

N1 - Brueckl: Paracelsus Med Univ, Gen Hosp Nuernberg, Dept Resp Med Allergol Sleep Med, Nurnberg, Germany

PY - 2017

Y1 - 2017

KW - SURVIVAL-DATA

KW - AFATINIB

KW - TRIAL

KW - GEFITINIB

U2 - 10.1016/S1470-2045(17)30684-8

DO - 10.1016/S1470-2045(17)30684-8

M3 - Editorial

C2 - 28958503

SN - 1470-2045

VL - 18

SP - 1425

EP - 1426

JO - LANCET ONCOL

JF - LANCET ONCOL

IS - 11

ER -